Sera Prognostics, Inc. (NASDAQ:SERA) Shares Sold by Invesco Ltd.

Invesco Ltd. lessened its stake in Sera Prognostics, Inc. (NASDAQ:SERA - Free Report) by 97.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 13,708 shares of the company's stock after selling 578,489 shares during the quarter. Invesco Ltd.'s holdings in Sera Prognostics were worth $112,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of SERA. JPMorgan Chase & Co. increased its stake in shares of Sera Prognostics by 7,357.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company's stock valued at $6,902,000 after purchasing an additional 873,002 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Sera Prognostics by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 599,702 shares of the company's stock worth $4,883,000 after buying an additional 12,865 shares during the period. Sanders Morris Harris LLC raised its stake in shares of Sera Prognostics by 165.7% during the 4th quarter. Sanders Morris Harris LLC now owns 90,600 shares of the company's stock worth $725,000 after buying an additional 56,500 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Sera Prognostics by 5.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 81,228 shares of the company's stock valued at $661,000 after purchasing an additional 4,115 shares in the last quarter. Finally, Barclays PLC lifted its holdings in Sera Prognostics by 321.6% during the third quarter. Barclays PLC now owns 39,450 shares of the company's stock valued at $308,000 after purchasing an additional 30,093 shares in the last quarter. Institutional investors and hedge funds own 54.64% of the company's stock.

Sera Prognostics Trading Up 4.7%

SERA traded up $0.10 during midday trading on Friday, hitting $2.22. 114,021 shares of the company traded hands, compared to its average volume of 131,027. The company has a market capitalization of $83.61 million, a price-to-earnings ratio of -2.24 and a beta of 0.99. Sera Prognostics, Inc. has a 52-week low of $2.10 and a 52-week high of $9.91. The business has a 50 day simple moving average of $3.48 and a two-hundred day simple moving average of $5.49.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.06 million. Equities research analysts anticipate that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.